Respiratory Syncytial Virus Diagnostic Testing Market

Respiratory Syncytial Virus Diagnostic Testing Market (Test Type: Antigen Detection Test, Molecular Diagnostic Test, Direct Fluorescent Antibody Test, Diagnostic Imaging, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Respiratory Syncytial Virus Diagnostic Testing Market Outlook 2031

  • The global industry was valued at US$ 884.9 Mn in 2022
  • It is projected to grow at a CAGR of 8.8% from 2022 to 2031 and reach more than US$ 1.9 Bn by 2031

Analysts’ Viewpoint on Market Scenario

Respiratory syncytial virus diagnostic testing market value is projected to increase at a brisk pace in the near future owing to the surge in awareness about Respiratory Syncytial Virus (RSV) infection, especially in developed countries, and rise in need for early diagnosis.

Emergence of COVID-19 has led to an increase in demand for respiratory diagnostic tests. Growth in prevalence of RSV, particularly among the elderly and young children, is projected to boost market progress during the forecast period. However, high cost of RSV diagnostic tests and lack of awareness about RSV infection in developing countries are likely to pose challenges to industry growth in the next few years.

Respiratory Syncytial Virus Diagnostic Testing Market

Market Introduction

Respiratory syncytial virus (RSV) is a highly contagious virus that primarily affects the respiratory tract (lungs and breathing passages). It is a common cause of upper and lower respiratory infections in infants, young children, and elderly people. The infection can lead to severe complications such as pneumonia and bronchiolitis.

Currently, no specific treatment is available for RSV. However, symptoms can be managed with supportive care. Prevention measures include good hygiene practices, such as frequent hand washing, and avoiding close contact with infected individuals.

RSV diagnostic tests come in various formats including laboratory-based tests, rapid antigen tests, and molecular tests. Laboratory-based tests, such as ELISA and PCR, provide highly accurate results. Rapid Antigen Diagnostic Tests (RADTs) provide quick results and are used in point-of-care settings. Molecular tests offer high accuracy and are widely employed in hospitals and diagnostic centers.

Rise in Incidence of RSV Infections Fueling Respiratory Syncytial Virus Diagnostic Testing Market Size

Increase in awareness about RSV and the need for early diagnosis are anticipated to boost the demand for RSV diagnostic tests in the next few years. Prevalence of RSV is high in young children and older adults. It is responsible for a significant number of hospitalizations and deaths in infants, children, and older adults, particularly among those with pre-existing respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD). Thus, increase in incidence of RSV infections is projected to spur the respiratory syncytial virus diagnostic testing market growth during the forecast period.

Emergence of the COVID-19 pandemic led to surge in demand for RSV diagnostic tests, as symptoms of RSV and COVID-19 are similar. The pandemic also put a strain on healthcare systems, thereby leading to a rise in need for rapid and accurate diagnostic tests. Thus, growth in cases of COVID-19 is estimated to augment market expansion in the near future.

R&D of Advanced Diagnostic Solutions

Robust diagnostic tests are crucial for the effective treatment and management of RSV infections. Molecular diagnostics methods such as Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) allow for rapid and accurate detection of RSV genetic material. Such advanced tests help improve the speed and accuracy of RSV diagnosis.

R&D of advanced diagnostic solutions is estimated to propel market statistics in the next few years. Speed and accuracy in diagnosis gained importance post the outbreak of COVID-19. Accurate and timely diagnosis became crucial to determine the most appropriate course of treatment, as COVID-19 and RSV infections had common characteristics. Thus, rapid antigen detection tests for RSV were deployed in many countries.

High Sensitivity of Antigen Detection Tests

According to the latest respiratory syncytial virus diagnostic testing market trends, the antigen detection test is expected to dominate the industry during the forecast period. Antigen detection tests are popular due to their high sensitivity, rapid results, and ability to detect RSV in the early stages of infection. Ease of use and low cost of antigen detection tests make them an attractive option for medical professionals and patients alike.

RADTs can produce results within 15 minutes. Numerous studies have demonstrated the accuracy of antigen detection tests in detecting RSV. A study published in the Journal of Clinical Microbiology found that RADTs offered a sensitivity of 97.1% in detecting RSV compared to a sensitivity of 94.1% for molecular diagnostics tests.

Significant Demand for Kits and Assays

According to the latest respiratory syncytial virus diagnostic testing market analysis, the kits and assays product segment is anticipated to account for the largest share during the forecast period. Kits and assays are easy to use, affordable, and highly accurate. Growth in awareness about RSV and increase in incidence of RSV-related illnesses are likely to propel the segment in the near future.

Kits and assays witnessed surge in demand post the emergence of COVID-19. Need for quick and accurate RSV testing became more critical, as health systems in various countries were overwhelmed by the rise in cases of COVID-19.

Independent Diagnostic Laboratories Gaining Traction

The independent diagnostic laboratories end-user segment is projected to dominate the market during the forecast period. Increase in prevalence of respiratory infections and rise in demand for accurate and reliable diagnostic tests are likely to boost the segment in the near future.

Independent diagnostic laboratories offer a wide range of RSV diagnostic tests that are quick, efficient, and highly accurate. This makes them a preferred choice for many patients and healthcare providers. Independent diagnostic laboratories have access to the latest diagnostic equipment and techniques. This allows them to provide accurate results within a short turnaround time.

Regional Outlook

According to the latest respiratory syncytial virus diagnostic testing market forecast, North America is estimated to hold the largest share from 2023 to 2031. High prevalence of RSV infections and presence of developed healthcare infrastructure are boosting market dynamics in the region. Additionally, R&D of new products is anticipated to drive the demand for RSV diagnostic tests.

The industry in Europe is expected to grow at a significant pace during the forecast period. Increase in cases of RSV infections and launch of new tests are fueling market development in the region. High prevalence of RSV infections and surge in investment in healthcare infrastructure are likely to boost the market revenue of Asia Pacific during the forecast period.

Analysis of Key Players

The respiratory syncytial virus diagnostic testing market report profiles prominent vendors based on various parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

F. Hoffmann-La Roche AG, Abbott, Thermo Fisher Scientific, BD (Becton, Dickinson and Company), QuidelOrtho Corporation, Hologic, Inc., Luminex Corporation, Agilent Technologies, Inc., Cepheid (Danaher Corporation), and DiaSorin S.p.A. are key players operating in this industry.

Leading companies are focusing on R&D of new products to increase their respiratory syncytial virus diagnostic testing market share. They are also adopting various organic and inorganic growth strategies to strengthen their market position.

Key Developments in Respiratory Syncytial Virus Diagnostic Testing Market

  • In October 2022, F. Hoffmann-La Roche AG received the U.S. Food and Drug Administration approval for the cobas SARS-CoV-2 Qualitative PCR test for use on the fully automated cobas 6800 and cobas 8800 Systems
  • In November 2021, F. Hoffmann-La Roche AG launched cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark

Respiratory Syncytial Virus Diagnostic Testing Market Snapshot

Attribute

Detail

Market Size Value in 2022

US$ 884.9 Mn

Market Forecast Value in 2031

More than US$ 1.9 Bn

Compound Annual Growth Rate (CAGR)

8.8%

Forecast Period

2023–2031

Historical Data Available for

2017–2022

Quantitative Units

US$ Mn/Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis/ranking by company (2022)
  • Company profiles section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Test Type
    • Antigen Detection Test
    • Molecular Diagnostic Test
    • Direct Fluorescent Antibody Test
    • Diagnostic Imaging
    • Others
  • Product
    • Kits and Assays
    • Instruments/Devices
  • End-user
    • Hospitals-attached Laboratories
    • Independent Diagnostic Laboratories
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • F. Hoffmann-La Roche AG
  • Abbott
  • Thermo Fisher Scientific
  • BD (Becton, Dickinson and Company)
  • QuidelOrtho Corporation
  • Hologic, Inc.
  • Luminex Corporation
  • Agilent Technologies, Inc.
  • Cepheid (Danaher Corporation)
  • DiaSorin S.p.A.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global respiratory syncytial virus diagnostic testing market in 2022?

It was valued at US$ 884.9 Mn in 2022.

How big will be the Respiratory Syncytial Virus Diagnostic Testing industry by 2031?

It is projected to reach more than US$ 1.9 Bn by the end of 2031.

What will be the CAGR during the forecast period?

It is anticipated to be 8.8% from 2023 to 2031.

Which are the prominent trends that affect business growth?

Rise in incidence of Respiratory Syncytial Virus (RSV) infections and approval and launch of new diagnostic solutions.

What was the Respiratory Syncytial Virus Diagnostic Testing Market share of the leading segment?

The kits and assays product segment held the largest share in 2022.

Which region will account for major Respiratory Syncytial Virus Diagnostic Testing Market share during the forecast period?

North America is expected to account for major share from 2023 to 2031.

Who are the prominent players operating in the sector?

F. Hoffmann-La Roche AG, Abbott, Thermo Fisher Scientific, BD (Becton, Dickinson and Company), QuidelOrtho Corporation, Hologic, Inc., Luminex Corporation, Agilent Technologies, Inc., Cepheid (Danaher Corporation), and DiaSorin S.p.A.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Respiratory Syncytial Virus Diagnostic Testing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Respiratory Syncytial Virus Diagnostic Testing Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Respiratory Syncytial Virus Diagnostic Testing Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projection (US$ Mn)

    5. Market Outlook

        5.1. Disease Incidence and Prevalence Across the Globe

        5.2. COVID-19 Impact on Industry

        5.3. Regulatory Scenario Across the Globe/Key Countries

    6. Global Respiratory Syncytial Virus Diagnostic Testing Market Analysis and Forecast, by Test Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Test Type, 2017–2031

            6.3.1. Antigen Detection Test

            6.3.2. Molecular Diagnostic Test

            6.3.3. Direct Fluorescent Antibody Test

            6.3.4. Diagnostic Imaging

            6.3.5. Others

        6.4. Market Attractiveness, by Test Type

    7. Global Respiratory Syncytial Virus Diagnostic Testing Market Analysis and Forecast, by Product

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Product, 2017–2031

            7.3.1. Kits and Assays

            7.3.2. Instruments/Devices

        7.4. Market Attractiveness, by Product

    8. Global Respiratory Syncytial Virus Diagnostic Testing Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by End-user, 2017–2031

            8.3.1. Hospitals-attached Laboratories

            8.3.2. Independent Diagnostic Laboratories

            8.3.3. Others

        8.4. Market Attractiveness, by End-user

    9. Global Respiratory Syncytial Virus Diagnostic Testing Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness, by Country/Region

    10. North America Respiratory Syncytial Virus Diagnostic Testing Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Test Type, 2017–2031

            10.2.1. Antigen Detection Test

            10.2.2. Molecular Diagnostic Test

            10.2.3. Direct Fluorescent Antibody Test

            10.2.4. Diagnostic Imaging

            10.2.5. Others

        10.3. Market Value Forecast, by Product, 2017–2031

            10.3.1. Kits and Assays

            10.3.2. Instruments/Devices

        10.4. Market Value Forecast, by End-user, 2017–2031

            10.4.1. Hospitals-attached Laboratories

            10.4.2. Independent Diagnostic Laboratories

            10.4.3. Others

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Test Type

            10.6.2. By Product

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Respiratory Syncytial Virus Diagnostic Testing Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Test Type, 2017–2031

            11.2.1. Antigen Detection Test

            11.2.2. Molecular Diagnostic Test

            11.2.3. Direct Fluorescent Antibody Test

            11.2.4. Diagnostic Imaging

            11.2.5. Others

        11.3. Market Value Forecast, by Product, 2017–2031

            11.3.1. Kits and Assays

            11.3.2. Instruments/Devices

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Hospitals-attached Laboratories

            11.4.2. Independent Diagnostic Laboratories

            11.4.3. Others

        11.5. Market Value Forecast, by Country, 2017–2031

            11.5.1. U.K.

            11.5.2. Germany

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Test Type

            11.6.2. By Product

            11.6.3. By End-user

            11.6.4. By Country

    12. Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Test Type, 2017–2031

            12.2.1. Antigen Detection Test

            12.2.2. Molecular Diagnostic Test

            12.2.3. Direct Fluorescent Antibody Test

            12.2.4. Diagnostic Imaging

            12.2.5. Others

        12.3. Market Value Forecast, by End-user, 2017–2031

            12.3.1. Kits and Assays

            12.3.2. Instruments/Devices

        12.4. Market Value Forecast, by End-user, 2017–2031

            12.4.1. Hospitals-attached Laboratories

            12.4.2. Independent Diagnostic Laboratories

            12.4.3. Others

        12.5. Market Value Forecast, by Country, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Test Type

            12.6.2. By Product

            12.6.3. By End-user

            12.6.4. By Country

    13. Latin America Respiratory Syncytial Virus Diagnostic Testing Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Test Type, 2017–2031

            13.2.1. Antigen Detection Test

            13.2.2. Molecular Diagnostic Test

            13.2.3. Direct Fluorescent Antibody Test

            13.2.4. Diagnostic Imaging

            13.2.5. Others

        13.3. Market Value Forecast, by Product, 2017–2031

            13.3.1. Kits and Assays

            13.3.2. Instruments/Devices

        13.4. Market Value Forecast, by End-user, 2017–2031

            13.4.1. Hospitals-attached Laboratories

            13.4.2. Independent Diagnostic Laboratories

            13.4.3. Others

        13.5. Market Value Forecast, by Country, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Test Type

            13.6.2. By Product

            13.6.3. By End-user

            13.6.4. By Country

    14. Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Test Type, 2017–2031

            14.2.1. Antigen Detection Test

            14.2.2. Molecular Diagnostic Test

            14.2.3. Direct Fluorescent Antibody Test

            14.2.4. Diagnostic Imaging

            14.2.5. Others

        14.3. Market Value Forecast, by Product, 2017–2031

            14.3.1. Kits and Assays

            14.3.2. Instruments/Devices

        14.4. Market Value Forecast, by End-user, 2017–2031

            14.4.1. Hospitals-attached Laboratories

            14.4.2. Independent Diagnostic Laboratories

            14.4.3. Others

        14.5. Market Value Forecast, by Country, 2017–2031

            14.5.1. GCC countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Test Type

            14.6.2. By Product

            14.6.3. By End-user

            14.6.4. By Country

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (by Tier and Size of Companies)

        15.2. Market Share Analysis by Company (2022)

        15.3. Company Profiles

            15.3.1. F. Hoffmann-La Roche AG

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Test Type Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. Abbott

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Test Type Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. Thermo Fisher Scientific

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Test Type Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. BD (Becton, Dickinson and Company)

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Test Type Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. QuidelOrtho Corporation

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Test Type Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Hologic, Inc.

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Test Type Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. Luminex Corporation

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Test Type Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Agilent Technologies, Inc.

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Test Type Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Cepheid (Danaher Corporation)

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Test Type Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

                15.3.9.5. Strategic Overview

            15.3.10. DiaSorin S.p.A.

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Test Type Portfolio

                15.3.10.3. Financial Overview

                15.3.10.4. SWOT Analysis

                15.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 02: Global Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Antigen Detection Test, 2017–2031

    Table 03: Global Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Molecular Diagnostic Test, 2017–2031

    Table 04: Global Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 05: Global Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 06: Global Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 07: North America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 08: North America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Antigen Detection Test, 2017–2031

    Table 09: North America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Molecular Diagnostic Test, 2017–2031

    Table 10: North America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 11: North America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 12: North America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 13: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 14: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Antigen Detection Test, 2017–2031

    Table 15: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Molecular Diagnostic Test, 2017–2031

    Table 16: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 17: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 18: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 19: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 20: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Antigen Detection Test, 2017–2031

    Table 21: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Molecular Diagnostic Test, 2017–2031

    Table 22: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 23: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 24: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 25: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 26: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Antigen Detection Test, 2017–2031

    Table 27: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Molecular Diagnostic Test, 2017–2031

    Table 28: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 29: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 30: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 31: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 32: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Antigen Detection Test, 2017–2031

    Table 33: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Molecular Diagnostic Test, 2017–2031

    Table 34: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 35: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 36: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Respiratory Syncytial Virus Diagnostic Testing Market

    Figure 02: Global Respiratory Syncytial Virus Diagnostic Testing Market Size (US$ Mn) Forecast, 2017–2031

    Figure 03: Global Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Test Type (2022)

    Figure 04: Global Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Product (2022)

    Figure 05: Global Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by End-user (2022)

    Figure 06: Global Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Region (2022)

    Figure 07: Global Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Test Type, 2022 and 2031

    Figure 08 Global Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Test Type, 2022–2031

    Figure 09: Global Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Product, 2022 and 2031

    Figure 10: Global Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Product, 2022–2031

    Figure 11: Global Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by End-user, 2022 and 2031

    Figure 12: Global Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by End-user, 2022–2031

    Figure 13: Global Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 14: Global Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Region, 2022–2031

    Figure 15: Global Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Region, 2022–2031

    Figure 16: North America Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Test Type, 2022 and 2031

    Figure 17: North America Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Test Type, 2022–2031

    Figure 18: North America Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Product, 2022 and 2031

    Figure 19: North America Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Product, 2022–2031

    Figure 20: North America Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by End-user, 2022 and 2031

    Figure 21: North America Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by End-user, 2022–2031

    Figure 22: North America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 23: North America Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Country, 2022–2031

    Figure 24: North America Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Country, 2022–2031

    Figure 25: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Test Type, 2022 and 2031

    Figure 26: Europe Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Test Type, 2022–2031

    Figure 27: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Product, 2022 and 2031

    Figure 28: Europe Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Product, 2022–2031

    Figure 29: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by End-user, 2022 and 2031

    Figure 30: Europe Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by End-user, 2022–2031

    Figure 31: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 32: Europe Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Country/Sub-region, 2022–2031

    Figure 33: Europe Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Country/Sub-region, 2022–2031

    Figure 34: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Test Type, 2022 and 2031

    Figure 35: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Test Type, 2022–2031

    Figure 36: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Product, 2022 and 2031

    Figure 37: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Product, 2022–2031

    Figure 38: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by End-user, 2022 and 2031

    Figure 39: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by End-user, 2022–2031

    Figure 40: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 41: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Country/Sub-region, 2022–2031

    Figure 42: Asia Pacific Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Country/Sub-region, 2022–2031

    Figure 43: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Test Type, 2022 and 2031

    Figure 44: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Test Type, 2022–2031

    Figure 45: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Product, 2022 and 2031

    Figure 46: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Product, 2022–2031

    Figure 47: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by End-user, 2022 and 2031

    Figure 48: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by End-user, 2022–2031

    Figure 49: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 50: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Country/Sub-region, 2022–2031

    Figure 51: Latin America Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Country/Sub-region, 2022–2031

    Figure 52: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Test Type, 2022 and 2031

    Figure 53: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Test Type, 2022–2031

    Figure 54: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Product, 2022 and 2031

    Figure 55: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Product, 2022–2031

    Figure 56: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by End-user, 2022 and 2031

    Figure 57: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by End-user, 2022–2031

    Figure 58: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 59: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Value Share, by Country/Sub-region, 2022–2031

    Figure 60: Middle East & Africa Respiratory Syncytial Virus Diagnostic Testing Market Attractiveness, by Country/Sub-region, 2022–2031

    Figure 61: Global Respiratory Syncytial Virus Diagnostic Testing Market Share Analysis, by Company, 2022 (Estimated)

    Figure 62: Global Respiratory Syncytial Virus Diagnostic Testing Market Performance, by Company, 2022

    Figure 63: Competition Matrix

Copyright © Transparency Market Research, Inc. All Rights reserved